TY - JOUR
T1 - Brimonidine Enhances the Electrophysiological Response of Retinal Ganglion Cells through the Trk-MAPK/ERK and PI3K Pathways in Axotomized Eyes
AU - Yukita, Masayoshi
AU - Omodaka, Kazuko
AU - Machida, Shigeki
AU - Yasuda, Masayuki
AU - Sato, Kota
AU - Maruyama, Kazuichi
AU - Nishiguchi, Koji M.
AU - Nakazawa, Toru
N1 - Funding Information:
This work was supported in part by JSPS KAKENHI Grants-in-Aid for Scientific Research B (T.N. 26293372), Challenging Exploratory Research (T.N. 26670751) and for Research Activity start-up (K.M.N. 26893018). This study was also supported by the JST Center for Revitalization Promotion (T.N.) and the National Institute of Biomedical Innovation (T.N) as well as SENJU Pharmaceutical Co., Ltd.
Publisher Copyright:
© 2016 Taylor & Francis.
PY - 2017/1/2
Y1 - 2017/1/2
N2 - Purpose: To investigate changes in retinal ganglion cell (RGC) activity by measuring the positive scotopic threshold response (pSTR) of the electroretinogram (ERG) in axotomized eyes after brimonidine injection. Methods: In 50 adult Sprague-Dawley rats, the left eye was axotomized and injected with phosphate buffered saline (PBS) or brimonidine and the contralateral right eye was left untreated. Scotopic ERGs were recorded simultaneously from both eyes on days 1, 2, 3, 7, and 10 after the intravitreal injection, and the amplitude of the a- and b-waves and the pSTR were measured. Surviving RGCs in the flat-mounted retinas were counted 10 days after axotomy. In addition to brimonidine, K252a (an inhibitor of tyrosine kinase phosphorylation of the Trk receptors), U0126 (a MAPK/ERK kinase inhibitor), and LY294002 (phosphoinositide 3-kinases [PI3Ks]) were also injected intravitreally into the left eye, and ERGs were recorded using the same protocol. Results: The pSTR amplitude increased significantly in the axotomized eyes with brimonidine, to 122.9 ± 5.0%, 161.8 ± 8.3%, and 133.6 ± 8.1% on days 1, 2, and 3 (P < 0.01), respectively, compared to the axotomized eyes treated with PBS (control). The increased pSTR amplitude returned to normal (103.6 ± 6.7%) on day 7, although there were a greater number of surviving RGCs in the treatment groups than in the controls. The intravitreal injection of K252a, U0126, or LY294002 significantly attenuated the increase in pSTR induced by intravitreal brimonidine (P < 0.01). Conclusion: Intravitreal brimonidine enhanced the survival and electrophysiological activity of the RGCs in rats. The mechanism of this electrophysiological change may involve activation of the Trk-MAPK/ERK and Trk-PI3K signals.
AB - Purpose: To investigate changes in retinal ganglion cell (RGC) activity by measuring the positive scotopic threshold response (pSTR) of the electroretinogram (ERG) in axotomized eyes after brimonidine injection. Methods: In 50 adult Sprague-Dawley rats, the left eye was axotomized and injected with phosphate buffered saline (PBS) or brimonidine and the contralateral right eye was left untreated. Scotopic ERGs were recorded simultaneously from both eyes on days 1, 2, 3, 7, and 10 after the intravitreal injection, and the amplitude of the a- and b-waves and the pSTR were measured. Surviving RGCs in the flat-mounted retinas were counted 10 days after axotomy. In addition to brimonidine, K252a (an inhibitor of tyrosine kinase phosphorylation of the Trk receptors), U0126 (a MAPK/ERK kinase inhibitor), and LY294002 (phosphoinositide 3-kinases [PI3Ks]) were also injected intravitreally into the left eye, and ERGs were recorded using the same protocol. Results: The pSTR amplitude increased significantly in the axotomized eyes with brimonidine, to 122.9 ± 5.0%, 161.8 ± 8.3%, and 133.6 ± 8.1% on days 1, 2, and 3 (P < 0.01), respectively, compared to the axotomized eyes treated with PBS (control). The increased pSTR amplitude returned to normal (103.6 ± 6.7%) on day 7, although there were a greater number of surviving RGCs in the treatment groups than in the controls. The intravitreal injection of K252a, U0126, or LY294002 significantly attenuated the increase in pSTR induced by intravitreal brimonidine (P < 0.01). Conclusion: Intravitreal brimonidine enhanced the survival and electrophysiological activity of the RGCs in rats. The mechanism of this electrophysiological change may involve activation of the Trk-MAPK/ERK and Trk-PI3K signals.
KW - Axonal injury
KW - BDNF
KW - brimonidine
KW - retinal ganglion cell
KW - scotopic threshold response
UR - http://www.scopus.com/inward/record.url?scp=84975113460&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84975113460&partnerID=8YFLogxK
U2 - 10.3109/02713683.2016.1153112
DO - 10.3109/02713683.2016.1153112
M3 - Article
C2 - 27314704
AN - SCOPUS:84975113460
VL - 42
SP - 125
EP - 133
JO - Current Eye Research
JF - Current Eye Research
SN - 0271-3683
IS - 1
ER -